求Future Oncol文献一篇【题名】：Abiraterone acetate：a promising drug for the treatment of castration-resistant prostate cancer
【作者】：Agarwal N, Hutson TE, Vogelzang NJ, Sonpavde G.
【年, 卷(期), 起止页码】： 2010 May;6(5):665-79
【摘要信息】：Abiraterone acetate (CB7630), a pregnenolone analog, is an orally administered small molecule
that irreversibly inhibits a rate-limiting enzyme in androgen biosynthesis, CYP17, and blocks the
synthesis of androgens in the testes, adrenal glands and prostate without causing adrenal
insufficiency. In clinical studies, abiraterone acetate is well tolerated and shows promising clinical
activity in castration-resistant prostate cancer. The recommended Phase II dose of abiraterone
acetate is 1000 mg orally daily in combination with prednisone 5 mg twice daily. Side effects are
minimal and mostly associated with secondary mineralocorticoid excess, owing to a
compensatory increase in upstream steroids, such as deoxycorticosterone and corticosterone.
These include hypertension, hypokalemia and edema and are easily manageable with a selective
mineralocorticoid antagonist, such as eplerenone, or low-dose corticosteroids. Currently,
abiraterone acetate is being tested in a Phase III trial for men with progressive castration-resistant
prostate cancer who are chemotherapy naive. A Phase III trial for patients following prior
chemotherapy has been completed and is awaiting analysis